- UK startup Healx lands $56M, led by Atomico to build an AI-driven clinical-stage portfolio for rare diseases, including treatments for fragile X syndrome, the leading genetic cause of autism.
- Healx’s Rare Treatment Accelerator program is a new initiative launched in close partnership with patient communities to identify clinic-ready treatments for rare diseases within 24 months.
Healx, a Cambridge, England-based AI-powered and patient-inspired technology company specializing in
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
Life Image, Graticule Partner to Help Biopharma Accelerate Drug Development
- Life Image partners with Graticule to help biopharma realize the full potential of advanced data in real-world evidence programs.
- Partnership combines Life Image’s global medical evidence network specializing in imaging data with Graticule’s deep expertise applying advanced data to high-value use cases.
Life Image, the world’s largest medical evidence network for clinical and imaging data has announced a new partnership with Graticule to help life sciences companies accelerate drug
Read More
CB Insights Unveils ‘Digital Health 150’ List of Startups Transforming Healthcare
- CB Insights unveils first-ever annual ‘Digital Health 150’ list of digital health startups working to transform the healthcare industry.
- The Digital Health 150 companies span a wide spectrum of categories that involve all three key stakeholder groups for the healthcare industry — providers, payers, and patients.
- A total of 17 companies on the list are unicorns (private companies valued at $1B+). Of these, 12 companies are US-based, 3 are based in China, 1 is based in France, and 1
Read More
Life Image Launches Real World Imaging for RWE Programs
- Life Image launches Real World Imaging (RWI) offering to respond to researcher needs for maturing insights and accelerating drug development decisions.
- Imaging data, especially for Real World Evidence (RWE), has historically been difficult, if not impossible, to access, retrieve, view, de-identify and normalize at-scale, even though it provides clinically material insights for a growing number of therapies.
- Life Image represents the only company providing large, heterogeneous,
Read More
Tufs Study: Cancer Drugs Now Account for 27% of all New Drug Approvals
Quick Glance- Cancer drugs currently account for 27% of all new drug approvals in the United States since 2010- From 1980 through 2018, the Food and Drug Administration (FDA) approved a total of 126 cancer drugs to treat solid and hematologic tumors- New approaches to development helped to drive the surge in new oncology products, including improvements in clinical trial design, novel drug formats, and a focus on new and validated targetsCancer drugs currently account for 27% of all new drug
Read More
Report: Precision Medicine Is Impossible Without AI and Machine Learning
Artificial intelligence (AI) and machine learning are driving a great deal of the healthcare innovation in precision medicine, according to a new Chilmark Research report. The report reveals achieving the full potential of precision medicine is impossible to realize without applying AI and machine learning. Specifically, leveraging advanced machine learning and deep learning technology can rapidly analyze large datasets that outperform clinicians and researchers. Precision Medicine: Making
Read More
Notable Nabs $40M to Expand Drug Discovery Platform for Personalized Oncology
Notable, a San Francisco, CA-based company redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development has raised $40M in Series B funding. The Series B round is co-led by B Capital Group and LifeForce Capital. LifeForce is a returning investor, joined by new investors B Capital and Industry Ventures. This latest round brings Notable’s total funding to over $55M.Notable was founded in 2017 by Matt De Silva after helping his own father Marc, who
Read More
Atomwise, Enamine Launches AI-Powered 10 Billion Compound Virtual Drug Screen for Pediatric Oncology
Atomwise announced the launch of a 10 billion compound AI-powered virtual drug screening initiative for pediatric oncology, in collaboration with Enamine Ltd., the world’s largest chemical supplier. The goal of this initiative – called the 10-to-the-10 program – is to dramatically increase the discovery of safer small molecules to treat pediatric cancers. When completed, it will stand as the largest ever virtual drug screen. 10-to-the-10 Program OverviewCancer is diagnosed in more than 15,000
Read More
Data-Driven Precision Medicine Startup Tempus Lands $200M to Expand Into New Therapeutic Areas
Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an additional $200M financing at a value of $3.1 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and funds and accounts managed by T. Rowe Price. With this latest round, the company has raised $520 million since its founding in September 2015.Founded in 2015, Tempus has the largest
Read More
LunaPBC Raises $4.6M to Fuel Community-Owned Genomic & Health Data Platform
LunaPBC, founder of LunaDNA, the first community-owned genomic and health data platform, has raised $4.6 million from ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Illumina Ventures, and Osage University Partners. The latest round brings the company’s total funding to date to $7.6 million.
First Community-Owned Health & DNA Research Platform
Founded in 2017 on the belief that health data sharing and community ownership are the new philanthropy, LunaDNA is the first
Read More
